$2.71T
Total marketcap
$95.3B
Total volume
BTC 49.79%     ETH 17.01%
Dominance

Kazia Therapeutics KZIA Stock

0.27 USD {{ price }} -1.611171% {{change_pct}}%
Exchange
NasdaqCM
Market Cap
7.24M USD
LOW - HIGH [24H]
0.26 - 0.29 USD
VOLUME [24H]
186.35K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-0.37 USD

Kazia Therapeutics Price Chart

Kazia Therapeutics KZIA Financial and Trading Overview

Kazia Therapeutics stock price 0.27 USD
Previous Close 1.26 USD
Open 1.24 USD
Bid 0 USD x 1300
Ask 0 USD x 1400
Day's Range 1.24 - 1.26 USD
52 Week Range 0.5 - 6.38 USD
Volume 7.54K USD
Avg. Volume 31.53K USD
Market Cap 25.75M USD
Beta (5Y Monthly) 2.269731
PE Ratio (TTM) N/A
EPS (TTM) -0.37 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 2.04 USD

KZIA Valuation Measures

Enterprise Value 16.75M USD
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) Infinity
Price/Book (mrq) 1.774648
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -0.725

Trading Information

Kazia Therapeutics Stock Price History

Beta (5Y Monthly) 2.269731
52-Week Change -76.091%
S&P500 52-Week Change 20.43%
52 Week High 6.38 USD
52 Week Low 0.5 USD
50-Day Moving Average 1.28 USD
200-Day Moving Average 1.02 USD

KZIA Share Statistics

Avg. Volume (3 month) 31.53K USD
Avg. Daily Volume (10-Days) 11.41K USD
Shares Outstanding 20.43M
Float 11.38M
Short Ratio 8.71
% Held by Insiders 0%
% Held by Institutions 1.89%
Shares Short 161.45K
Short % of Float N/A
Short % of Shares Outstanding 0.79%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:4

Financial Highlights

Fiscal Year

Fiscal Year Ends June 30, 2022
Most Recent Quarter (mrq) December 31, 2022
Next Fiscal Year End June 30, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) 0%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -43.19%
Return on Equity (ttm) -135.030%

Income Statement

Revenue (ttm) 0 USD
Revenue Per Share (ttm) 0 USD
Quarterly Revenue Growth (yoy) -99.70%
Gross Profit (ttm) 10K USD
EBITDA -23103516 USD
Net Income Avi to Common (ttm) -25031994 USD
Diluted EPS (ttm) -1.16
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 4.39M USD
Total Cash Per Share (mrq) 0.27 USD
Total Debt (mrq) 552.32K USD
Total Debt/Equity (mrq) 4.77 USD
Current Ratio (mrq) 1.06
Book Value Per Share (mrq) 0.71

Cash Flow Statement

Operating Cash Flow (ttm) -20177400 USD
Levered Free Cash Flow (ttm) -14297770 USD

Profile of Kazia Therapeutics

Country United States
State NSW
City Sydney
Address Three International Towers
ZIP 2000
Phone N/A
Website https://www.kaziatherapeutics.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees N/A

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.

Q&A For Kazia Therapeutics Stock

What is a current KZIA stock price?

Kazia Therapeutics KZIA stock price today per share is 0.27 USD.

How to purchase Kazia Therapeutics stock?

You can buy KZIA shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Kazia Therapeutics?

The stock symbol or ticker of Kazia Therapeutics is KZIA.

Which industry does the Kazia Therapeutics company belong to?

The Kazia Therapeutics industry is Biotechnology.

How many shares does Kazia Therapeutics have in circulation?

The max supply of Kazia Therapeutics shares is 26.36M.

What is Kazia Therapeutics Price to Earnings Ratio (PE Ratio)?

Kazia Therapeutics PE Ratio is now.

What was Kazia Therapeutics earnings per share over the trailing 12 months (TTM)?

Kazia Therapeutics EPS is -0.37 USD over the trailing 12 months.

Which sector does the Kazia Therapeutics company belong to?

The Kazia Therapeutics sector is Healthcare.

Kazia Therapeutics KZIA included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 17019.88 USD
+0.59
5.94B USD 16917.51 USD 17032.66 USD 5.94B USD
NASDAQ Capital Market Composite RCMP 112.85 USD
-1.03
112.07 USD 114.75 USD
NASDAQ HealthCare IXHC 978.74 USD
-1.03
973.64 USD 990.74 USD